Literature DB >> 19204869

Silencing of cytosolic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine.

Su-Min Lee1, Sin Young Park, Seoung Woo Shin, In Sup Kil, Eun Sun Yang, Jeen-Woo Park.   

Abstract

Staurosporine induces the production of reactive oxygen species, which play an important causative role in apoptotic cell death. Recently, it was demonstrated that the control of cellular redox balance and the defense against oxidative damage is one of the primary functions of cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDPc) by supplying NADPH for antioxidant systems. The present report shows that silencing of IDPc expression in HeLa cells greatly enhances apoptosis induced by staurosporine. Transfection of HeLa cells with an IDPc small interfering RNA (siRNA) markedly decreased activity of IDPc, enhancing the susceptibility of staurosporine-induced apoptosis reflected by DNA fragmentation, cellular redox status and the modulation of apoptotic marker proteins. These results indicate that IDPc may play an important role in regulating the apoptosis induced by staurosporine and the sensitizing effect of IDPc siRNA on the apoptotic cell death of HeLa cells offers the possibility of developing a modifier of cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204869     DOI: 10.1080/10715760802653661

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  10 in total

1.  Mitochondrial proteomic analysis reveals deficiencies in oxygen utilization in medullary thick ascending limb of Henle in the Dahl salt-sensitive rat.

Authors:  Nadezhda N Zheleznova; Chun Yang; Robert P Ryan; Brian D Halligan; Mingyu Liang; Andrew S Greene; Allen W Cowley
Journal:  Physiol Genomics       Date:  2012-07-17       Impact factor: 3.107

Review 2.  Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.

Authors:  Nicole Colwell; Mioara Larion; Amber J Giles; Ashlee N Seldomridge; Saman Sizdahkhani; Mark R Gilbert; Deric M Park
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

3.  The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.

Authors:  Fonnet E Bleeker; Nadia A Atai; Simona Lamba; Ard Jonker; Denise Rijkeboer; Klazien S Bosch; Wikky Tigchelaar; Dirk Troost; W Peter Vandertop; Alberto Bardelli; Cornelis J F Van Noorden
Journal:  Acta Neuropathol       Date:  2010-02-04       Impact factor: 17.088

Review 4.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

Authors:  Zachary J Reitman; Hai Yan
Journal:  J Natl Cancer Inst       Date:  2010-05-31       Impact factor: 11.816

5.  Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.

Authors:  Daniel Krell; Mawuelikem Assoku; Malcolm Galloway; Paul Mulholland; Ian Tomlinson; Chiara Bardella
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.752

6.  Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication.

Authors:  Ping Song; Huanhuan Wei; Zhengyu Cao; Peng Wang; Guoping Zhu
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

7.  Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.

Authors:  Pingcuo Laba; Jianfeng Wang; Jin Zhang
Journal:  BMC Cancer       Date:  2018-08-28       Impact factor: 4.430

Review 8.  Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance.

Authors:  Weihua Zhou; Daniel R Wahl
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

9.  A role for cytosolic isocitrate dehydrogenase as a negative regulator of glucose signaling for insulin secretion in pancreatic ß-cells.

Authors:  Claudiane Guay; Erik Joly; Emilie Pepin; Annie Barbeau; Lisa Hentsch; Marco Pineda; S R Murthy Madiraju; Henri Brunengraber; Marc Prentki
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

Review 10.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.